Loading...
Loading...
THTX| Name | Value |
|---|---|
| Revenues | 23.5M |
| Cost of Revenue | 5.1M |
| Gross Profit | 18.4M |
| Operating Expense | 15.7M |
| Operating I/L | 2.7M |
| Other Income/Expense | -5.4M |
| Interest Income | 0.2M |
| Pretax | -2.7M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -2.8M |
Theratechnologies Inc. is a biopharmaceutical company specializing in the development and commercialization of therapies to address unmet medical needs in the United States, Canada, and Europe. The company's key products include EGRIFTA and EGRIFTA SV, designed to reduce excess abdominal fat in HIV-infected patients with lipodystrophy, and Trogarzo, an injection for the treatment of multidrug-resistant HIV-1 infected patients. Additionally, Theratechnologies Inc. has a pipeline of products, including F8 Formulation for the treatment of lipodystrophy in people living with HIV, TH1902 for triple negative breast cancer, and TH1904 for ovarian cancer.
